Literature DB >> 19626400

Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study.

Yilmaz Gunes1, Unal Guntekin, Mustafa Tuncer, Musa Sahin.   

Abstract

Downregulation of glucose and fatty acid oxidation occurs in heart failure (HF). Trimetazidine reduces fatty acid oxidation and increases glucose oxidation. In this single-blind study, trimetazidine, 20 mg three times per day (n = 51) or placebo (n = 36) was added to treatment of 87 HF patients receiving optimal HF therapy. Etiology of heart failure was coronary artery disease in 35 patients (68.6%) in the trimetazidine group and 22 (62.9%) in the placebo group. Fourteen (27.5%) patients in the trimetazidine group and 11 (31.4%) patients in the placebo group had diabetes. Peak systolic velocity (Vs), and the peak early diastolic (Vd) and late diastolic (Va) velocities of various segments left and right ventricles (RV) were obtained with tissue Doppler imaging (TDI) and averaged. Patients were re-evaluated three months later. Significant increases in mean left ventricular ejection fraction (LVEF) (33.3% +/- 5.6% to 42.4% +/- 6.3%, P < 0.001 and 30.6% +/- 8.2% to 33.2% +/- 6.6%, P = 0.021) and LV and RV myocardial velocities and mitral and tricuspid annular TDI velocities were observed in both groups. However, compared to placebo, increments in LVEF (9.1% +/- 4.2% vs. 2.5% +/- 1.4%, P < 0.001) and myocardial velocities were significantly higher with trimetazidine (P < 0.001 for LV Vs, Vd, Va; P = 0.035 for RV Vd; and P < 0.001 for RV Va and Vs). Increase in LVEF with trimetazidine was significantly correlated with presence of diabetes (r = 0.524, P < 0.001). With trimetazidine LVEF increased significantly more in diabetic patients compared to nondiabetics (P < 0.001). Also, patients having both diabetes and ischemic HF tended to have greater improvement in LVEF compared to ischemic HF patients without diabetes (P = 0.063). Addition of trimetazidine to current treatment of HF, especially for those who are diabetic, may improve LV and RV functions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19626400     DOI: 10.1007/s00380-008-1118-x

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  27 in total

1.  Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function.

Authors:  J Meluzín; L Spinarová; J Bakala; J Toman; J Krejcí; P Hude; T Kára; M Soucek
Journal:  Eur Heart J       Date:  2001-02       Impact factor: 29.983

2.  Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.

Authors:  L Brottier; J L Barat; C Combe; B Boussens; J Bonnet; H Bricaud
Journal:  Eur Heart J       Date:  1990-03       Impact factor: 29.983

3.  Physiological cardiac reserve: development of a non-invasive method and first estimates in man.

Authors:  G A Cooke; P Marshall; J K al-Timman; D J Wright; R Riley; R Hainsworth; L B Tan
Journal:  Heart       Date:  1998-03       Impact factor: 5.994

4.  Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value.

Authors:  Mei Wang; Gabriel W K Yip; Angela Y M Wang; Yan Zhang; Pik Yuk Ho; Mui Kiu Tse; Peggo K W Lam; John E Sanderson
Journal:  J Am Coll Cardiol       Date:  2003-03-05       Impact factor: 24.094

Review 5.  Energy metabolism of the heart: from basic concepts to clinical applications.

Authors:  H Taegtmeyer
Journal:  Curr Probl Cardiol       Date:  1994-02       Impact factor: 5.200

Review 6.  Metabolic disturbances in diabetic cardiomyopathy.

Authors:  B Rodrigues; M C Cam; J H McNeill
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

7.  Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.

Authors:  Pericle Di Napoli; Paolo Di Giovanni; Marta Assunta Gaeta; Giuseppina D'Apolito; Antonio Barsotti
Journal:  Am Heart J       Date:  2007-09       Impact factor: 4.749

8.  Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.

Authors:  G Fragasso; P M Piatti Md; L Monti; A Palloshi; E Setola; P Puccetti; G Calori; G D Lopaschuk; A Margonato
Journal:  Am Heart J       Date:  2003-11       Impact factor: 4.749

Review 9.  Cardioprotective effects of trimetazidine: a review.

Authors:  Mario Marzilli
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

10.  Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.

Authors:  Giuseppe M C Rosano; Cristiana Vitale; Barbara Sposato; Giuseppe Mercuro; Massimo Fini
Journal:  Cardiovasc Diabetol       Date:  2003-11-28       Impact factor: 9.951

View more
  16 in total

1.  Cross-sectional relationship of a Mediterranean type diet to diastolic heart function in chronic heart failure patients.

Authors:  Christina Chrysohoou; Christos Pitsavos; George Metallinos; Christos Antoniou; Evaggelos Oikonomou; Iason Kotroyiannis; Apostolis Tsantilas; George Tsitsinakis; Dimitris Tousoulis; Demosthenes B Panagiotakos; Christodoulos Stefanadis
Journal:  Heart Vessels       Date:  2011-09-27       Impact factor: 2.037

Review 2.  The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.

Authors:  John J Ryan; Stephen L Archer
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

3.  Improvement of mechanical heart function by trimetazidine in db/db mice.

Authors:  Yuan-jing Li; Pei-hua Wang; Chen Chen; Ming-hui Zou; Dao-wen Wang
Journal:  Acta Pharmacol Sin       Date:  2010-04-12       Impact factor: 6.150

4.  Relation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and left atrial volume index to left ventricular function in chronic hemodialysis patients.

Authors:  Mayuko Yamazaki; Tetsuya Ogawa; Noriko Tamei; Yoshitaka Ando; Kosaku Nitta
Journal:  Heart Vessels       Date:  2010-12-03       Impact factor: 2.037

5.  Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle.

Authors:  Yong-Hu Fang; Lin Piao; Zhigang Hong; Peter T Toth; Glenn Marsboom; Peter Bache-Wiig; Jalees Rehman; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2011-08-28       Impact factor: 4.599

Review 6.  Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure.

Authors:  Lin Piao; Glenn Marsboom; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2010-09-04       Impact factor: 4.599

7.  Effects of hemodialysis on the cardiovascular system: quantitative analysis using wave intensity wall analysis and tissue velocity imaging.

Authors:  Anna Bjällmark; Matilda Larsson; Jacek Nowak; Britta Lind; Shirley Yumi Hayashi; Marcelo Mazza do Nascimento; Miguel C Riella; Astrid Seeberger; Lars-Åke Brodin
Journal:  Heart Vessels       Date:  2010-11-10       Impact factor: 2.037

8.  Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model.

Authors:  Angelical S Martin; Dennis M Abraham; Kathleen A Hershberger; Dhaval P Bhatt; Lan Mao; Huaxia Cui; Juan Liu; Xiaojing Liu; Michael J Muehlbauer; Paul A Grimsrud; Jason W Locasale; R Mark Payne; Matthew D Hirschey
Journal:  JCI Insight       Date:  2017-07-20

9.  Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure.

Authors:  Elena N Dedkova; Lea K Seidlmayer; Lothar A Blatter
Journal:  J Mol Cell Cardiol       Date:  2013-02-04       Impact factor: 5.000

Review 10.  Molecular Mechanisms of Right Ventricular Failure.

Authors:  Sushma Reddy; Daniel Bernstein
Journal:  Circulation       Date:  2015-11-03       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.